{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:19:44Z","timestamp":1783437584205,"version":"3.54.6"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,7,7]]},"DOI":"10.1001\/jama.2026.5242","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:30:40Z","timestamp":1779982240000},"page":"75","source":"Crossref","is-referenced-by-count":0,"title":["Nalbuphine for Cough Caused by Idiopathic Pulmonary Fibrosis\u2014Reply"],"prefix":"10.1001","volume":"336","author":[{"given":"Vandana","family":"Mathur","sequence":"first","affiliation":[{"name":"Mathur Consulting, Woodside, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Molyneaux","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cassella","sequence":"additional","affiliation":[{"name":"Trevi Therapeutics, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"jlr260035r1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/jama.2025.26179","article-title":"Oral nalbuphine in idiopathic pulmonary fibrosis\u2013associated cough: the CORAL randomized clinical trial.","volume":"335","author":"Molyneaux","year":"2026","journal-title":"JAMA"},{"issue":"11","key":"jlr260035r2","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1213\/00000539-198711000-00007","article-title":"Antagonism of postoperative opioid-induced respiratory depression: nalbuphine versus naloxone.","volume":"66","author":"Bailey","year":"1987","journal-title":"Anesth Analg"},{"issue":"3","key":"jlr260035r3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0022-3565(25)24168-4","article-title":"Antagonist effects of nalbuphine in opioid-dependent human volunteers.","volume":"248","author":"Preston","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"jlr260035r4","unstructured":"Nalbuphine hydrochloride package insert. December 2025. Accessed April 6, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/018024s044lbl.pdf"},{"key":"jlr260035r5","unstructured":"Naloxone hydrochloride package insert. February 2022. Accessed April 6, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215457s000lbl.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2849513\/jama_mathur_2026_lr_260035_1782490549.61739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:12:59Z","timestamp":1783437179000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2849513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,7]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.5242","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}